Source: Annual Congress 2008 - Recent advances in the pathogenesis and treatment of asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
N. Umeda, T. Yoshikawa, H. Kanazawa, S. Fujimoto, K. Hirata (Osaka, Japan). Association of β₂-adrenoceptor genotypes with bronchodilatory effect of tiotropium in COPD. Eur Respir J 2008; 32: Suppl. 52, 4186

Member's Comments

No comment yet.

Related content which might interest you: Association of β2-adrenoreceptor genotypes with prevention of COPD exacerbations by tiotropium or salmeterol in the POET-COPD® trial Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012 The bronchodilatory effect of NVA237 inhaled once daily in patients with COPD Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010 The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD Source: Eur Respir J 2006; 28: Suppl. 50, 212s Year: 2006 The effect of tiotropium in the treatment of patients with COPD Source: Annual Congress 2010 - COPD: management Year: 2010 The effect of tiotropium in COPD complicated with asthma Source: Annual Congress 2007 - New insights into the treatment of COPD Year: 2007 The effect of formoterol in elderly COPD patients Source: Eur Respir J 2005; 26: Suppl. 49, 122s Year: 2005 Bronchodilator efficacy of tiotropium in patients with mild COPD Source: Eur Respir J 2006; 28: Suppl. 50, 616s Year: 2006 Effects of procaterol or salmeterol added to maintenance tiotropium therapy on small airway functions in COPD patients Source: Annual Congress 2010 - COPD: management Year: 2010 Comparison of spirometric efficacy of fluticasone/salmeterol plus tiotropium and tiotropium alone in moderate COPD Source: Annual Congress 2009 - New bronchodilators Year: 2009 Differentiation of bronchodilator effects of indacaterol and formoterol by FEV1 and inspiratory capacity (IC) in patients with COPD Source: Annual Congress 2007 - New drugs for COPD Year: 2007 Effects of acute dual bronchodilator treatment (tiotropium + olodaterol) on cardiopulmonary interactions in hyperinflated patients with COPD Source: International Congress 2018 – Advances in exercise physiopathology Year: 2018 Beclomethasone, formoterol and glycopyrronium: ceiling effect in small airways of COPD patients Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD Year: 2020 COPD: Comparison of bronchodilator responsiveness with glycopyrronium and salbutamol Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Spirometric outcomes of COPD patients with tiotropium compared with salmeterol according to previous maintenance long-acting beta-agonist use Source: Eur Respir J 2004; 24: Suppl. 48, 289s Year: 2004 Comparison of indacaterol with tiotropium or once-daily dual long-acting bronchodilator therapy with roflumilast for severe COPD Source: International Congress 2014 – Markers Year: 2014 Comparative effects of formoterol monotherapy versus formoterol plus tiotropium on dynamic hyperinflation and exercise tolerance in COPD Source: Annual Congress 2009 - Influence of interventions and comorbidity on exercise performance Year: 2009 Association of β2-adrenoreceptor genotype with bronchodilator responses (bdr) in COPD Source: Annual Congress 2009 - Drug effects in COPD Year: 2009 Adding glycopyrronium to beclomethasone/formoterol combination: synergistic effect on human small airways of COPD donors Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021 Efficacy of nebulized arformoterol, a long-acting β2-adrenergic bronchodilator, in patients with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 215s Year: 2006 The fixed-dose combination of tiotropium + olodaterol has a rapid onset of action in patients with COPD Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015